– ITALY, Milan – Enthera Pharmaceuticals, a biotech company developing disease-modifying biologics to transform the therapeutic paradigm of specific autoimmune conditions by re-establishing stem cell capabilities in a non-traditional way, today announced the appointment of Dr. Kazumi Shiosaki, Ph.D. to its Board of Directors and Dr. Lisa Olson, Ph.D. to its Scientific Advisory Board.
Kazumi and Lisa will work closely with the leadership team and other Board and Scientific Advisors to support the growth and development of Enthera.
“The appointment of Kazumi Shiosaki and Lisa Olson will greatly benefit Enthera. Kazumi is a biotech veteran with an outstanding track record in corporate development and fundraising across both European and US markets, while Lisa brings extensive experience in drug discovery and development from roles at Magenta Therapeutics, AbbVie and Pfizer. The support of Kazumi and Lisa will be instrumental as we progress our pipeline and take Enthera to the next level.” said CEO, Giovanni Amabile.
About Kazumi Shiosaki
Kazumi brings experience as both an entrepreneur and an investor within the field of biotechnology. She is currently the CEO of Twentyeight-Seven, a biotech company focused on novel RNA biology that she co-founded alongside prominent Harvard investigators. Kazumi was also a co-founder and CEO of Mitobridge, a start-up company developing mitochondrial drugs for the treatment of muscle and kidney diseases, until its acquisition by Astellas Pharma in 2018. Before Mitobridge, she was a co-founder and start-up CEO of Epizyme (NASDAQ: EPZM), a leader in novel epigenetic therapeutics for cancer. She has also been a Managing Director at MPM Capital.
Kazumi Shioshaki said: “Enthera Pharmaceuticals is exciting young biotech, with an innovative and unique approach to treating underserved autoimmune disorders. The recent Series A financing round was a great achievement, and I look forward to working with the Enthera team as we push onwards and use these funds to build a world-class international company with first-in-class therapeutics.”
Kazumi started her career at AbbVie and from there joined Millennium, where she worked in senior functions in both research and corporate development. She is also a Board member of the Sandford Burnham Prebys Institute. Kazumi holds a Ph.D. in Synthetic Chemistry from UC Berkeley.
About Lisa Olson
Lisa is a senior pharmaceutical executive with more than 20 years of experience in research and drug discovery. She is currently CSO and Head of Research at Magenta Therapeutics, where she provides strategic direction, oversight, and execution for research and discovery efforts. Lisa joined Magenta after 15 years in leadership positions at the AbbVie Bioresearch Center, most recently as VP, Immunology Discovery and Site Head, where she was responsible for all immunology discovery scientific and portfolio decisions. Before AbbVie, Lisa served as a Research Fellow and Group Leader in Inflammation & Immunology at Pfizer.
Lisa Olson commented: “I look forward to supporting Giovanni and the rest of the Enthera team in the progression of their clinical assets. The Company’s lead product is a promising biologic candidate for type 1 diabetes and gastrointestinal diseases, with the wider pipeline offering potential treatments for several underserved autoimmune conditions.”
Lisa began her career as Assistant Professor at Washington University School of Medicine, following a post-doctoral cardiovascular fellowship at the University of Chicago. She holds a Ph.D. from the University of Illinois at Urbana-Champaign and a Bachelor of Science from Iowa State University.
Enthera Srl is a biotech company developing first-in-class biologics to transform the treatment paradigm of specific autoimmune conditions by re-establishing stem cell capabilities in a non-traditional way. The Company’s primary target indications are type 1 diabetes and inflammatory bowel disease.
Enthera’s pioneering approach capitalizes on the key discovery of the IGFBP3/TMEM219 pathway, which is involved in the beta-cell and stem cell apoptosis in the pancreas and gut, respectively.
The Company is building a pipeline of inhibitory monoclonal antibodies and fusion proteins targeting the pathway via multiple angles. Its lead program Ent001 is the only drug in development with the potential to restore the endogenous pancreatic stem cell compartment in T1D as well as the original intestine structure in IBD, to re-establish organ function.
Enthera is a private company headquartered in Milan, Italy, and founded in 2016 by Prof Paolo Fiorina and Dr. Francesca D’Addio at BiovelocITA, an Italian biotech accelerator. The Company is backed by Sofinnova Partners and JDRF T1D fund. Enthera’s discovery engine and assets are protected by a broad portfolio of patents.
Enthera recently closed a EUR 28 million funding, with investment from renowned investors Sofinnova Partners, AbbVie, and JDRF T1D Fund. The funds will be used to accelerate the Company’s lead program, Ent001, to clinical proof-of-concept.
For more information: https://www.entherapharmaceuticals.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.